1 Flashcards
(9 cards)
1
Q
what is drug discovery
A
a compound is found which is biologically active in the desired therapeutic area
2
Q
what is drug development
A
a compound discovered to be biologically active then has that activity and its toxically optimized for the clinic
3
Q
6 steps to drug discovery
A
- observation of a beneficial effect
- identification of component with positive attributes
- identification of target
- improved compound
- formulation
- development continues
4
Q
what is a me too compound
A
a drug containing an active pharmaceutical ingredient which is chemically related and very structurally similar to an existing API
5
Q
what design rationale does me too compounds use and how do they differ
A
- improvement of existing drugs
- series of derivatives were made based on the rationally designed drug
6
Q
5 things you look for when making me too compounds
A
- avoid patent issue
- improve efficacy
- improve safety profile
- allow for improved formulation which is easier to administer
- improved physical properties which affects pharmacokinetic parameters
7
Q
7 pros of me too compounds
A
- high probability of ending up with an active molecule
- if enough copies are made then there is a good chance of finding a compound with an improvement on the efficient of the original
- show a different profile of adverse effects (e.g. improve safety profile)
- previous info about the original drug is available
- can work in patients who don’t react to original drug
- can be less expensive than the original or drive down prices
- occasionally, very different properties discovered
8
Q
4 cons of me too compounds
A
- not very innovative
- can be seen as simply a way of propping up the pharmaceutical industry with minimal effort
- patient are often difficult to get around and the original inventor will already have covered most variation
- unlikely to lead to any dramatic or radical improvement over existing treatments
9
Q
3 ways to increase half-life
A
- add groups which prevent elimination of molecule
- and/or increase binding strength of the compound
- addition of a halogen to block metabolite formation extends half-life